NCT03361020

Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation

Active, enrolled Last updated 17 April 2026

What this trial tests

trial in Obstructive Sleep Apnea in 434 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 January 2018

Primary endpoint
31 July 2023

10 July 2028

Quick facts

Lead sponsor	St. Jude Children's Research Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	434
Start date	23 January 2018
Primary completion	31 July 2023
Estimated completion	10 July 2028
Sites	1 location across United States

Conditions studied

• Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
• Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

St. Jude Children's Research Hospital

Who can join

18 and older, any sex, with Obstructive Sleep Apnea or Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness. Insufficient sleep is recognized as an important public health concern, and is associated with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality of life and productivity.

Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with the added risk associated with obstructive sleep apnea (OSA). The investigators propose to examine indices of sleep quality using polysomnography, and associated neurocognitive performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult survivors of Hodgkin lymphoma treated with thoracic radiation.

OBJECTIVES:

1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic radiation, and compare the frequency to community controls matched on age, gender, race and body mass index.
2. To identify specific therapeutic factors associated with OSA in adult survivors of HL treated with thoracic radiation.
3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation.
4. To examine associations between OSA and cardiac morbidity and brain integrity in the adult survivors of HL treated with thoracic radiation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.